HURA
TuHURA Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.14
+1.90%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 23.5K | — | — | 55.0K | 60.0K |
| Gross Profit | (23.5K) | — | — | (55.0K) | (60.0K) |
| Operating Expenses | |||||
| R&D Expense | 22.9M | 20.5M | 13.3M | 2.7M | 9.3M |
| SG&A Expense | 4.6M | 7.6M | 3.9M | 5.7M | 5.4M |
| General & Admin Expense | 4.6M | 7.6M | 3.9M | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 3.7M | 3.7M | 440.3K | — | — |
| Total Operating Expenses | 31.2M | 31.8M | 17.6M | 8.4M | 14.7M |
| Cost and Expenses | 31.2M | 31.8M | 17.6M | 8.5M | 14.8M |
| Operating Income (EBIT) | (31.2M) | (31.8M) | (17.6M) | (8.5M) | (14.8M) |
| Non-Operating | |||||
| Interest Income | 35.6K | 136.2K | 361.6K | 89.7K | 57.4K |
| Interest Expense | 1.1M | 625.3K | 4.1M | 18.7K | — |
| Net Interest Income | (1.1M) | (489.1K) | (3.8M) | 71.0K | 57.4K |
| Other Non-Op Income/Expense | 572.5K | 1.7M | (4.0M) | 131.0K | 147.0K |
| Non-Operating Income (excl Interest) | (1.7M) | (2.4M) | (105.5K) | (131.0K) | (147.0K) |
| EBT (Pre-Tax Income) | (30.6M) | (30.1M) | (21.7M) | (8.3M) | (14.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (30.6M) | (30.1M) | (21.7M) | (8.3M) | (14.6M) |
| Earnings from Cont. Ops | (30.6M) | (30.1M) | (21.7M) | (8.3M) | (14.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (30.6M) | (30.1M) | (22.6M) | (8.5M) | (15.0M) |
| Per Share | |||||
| Basic EPS | ($0.54) | ($0.63) | ($1.21) | ($11.29) | ($324.48) |
| Diluted EPS | ($0.54) | ($0.63) | ($1.21) | ($11.29) | ($324.48) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 64.0M | 47.9M | 18.7M | 752914 | 46285 |
| Diluted Shares Outstanding | 64.0M | 47.9M | 18.7M | 752914 | 46285 |
| Profitability Metrics | |||||
| EBITDA | (29.4M) | (29.4M) | (17.4M) | (8.3M) | (14.6M) |
| D&A | 95.4K | 71.3K | 116.7K | 55.0K | 60.0K |
| EBIT | (29.5M) | (29.4M) | (17.5M) | (8.3M) | (14.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026